These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 27905519)
61. The Glasgow Prognostic Score (GPS) is a novel prognostic indicator in advanced epithelial ovarian cancer: a multicenter retrospective study. Zhu J; Wang H; Liu CC; Lu Y; Tang H J Cancer Res Clin Oncol; 2016 Nov; 142(11):2339-45. PubMed ID: 27566683 [TBL] [Abstract][Full Text] [Related]
62. Significance of MNK1 in prognostic prediction and chemotherapy development of epithelial ovarian cancer. Hou S; Du P; Wang P; Wang C; Liu P; Liu H Clin Transl Oncol; 2017 Sep; 19(9):1107-1116. PubMed ID: 28332091 [TBL] [Abstract][Full Text] [Related]
63. Loss of ITM2A, a novel tumor suppressor of ovarian cancer through G2/M cell cycle arrest, is a poor prognostic factor of epithelial ovarian cancer. Nguyen TM; Shin IW; Lee TJ; Park J; Kim JH; Park MS; Lee EJ Gynecol Oncol; 2016 Mar; 140(3):545-53. PubMed ID: 26691219 [TBL] [Abstract][Full Text] [Related]
64. Ki-67 as an independent prognostic factor in an unselected cohort of patients with ovarian cancer: results of an explorative, retrospective study. Battista MJ; Mantai N; Sicking I; Cotarelo C; Weyer V; Lebrecht A; Solbach C; Schmidt M Oncol Rep; 2014 May; 31(5):2213-9. PubMed ID: 24627004 [TBL] [Abstract][Full Text] [Related]
65. Polymorphic thymidylate synthase gene impacts on overall survival of patients with epithelial ovarian cancer after platinum-based chemotherapy. Biason P; Visentin M; Talamini R; Stopar A; Giorda G; Lucia E; Campagnutta E; Toffoli G Pharmacogenomics; 2012 Nov; 13(14):1609-19. PubMed ID: 23148637 [TBL] [Abstract][Full Text] [Related]
66. Identification of sequence nucleotide polymorphisms in the D-loop region of mitochondrial DNA as a risk factor for epithelial ovarian cancer. Liu S; Shi S; Li Y; Kong D Mitochondrial DNA A DNA Mapp Seq Anal; 2016; 27(1):9-11. PubMed ID: 24438298 [TBL] [Abstract][Full Text] [Related]
67. Being treated in higher volume hospitals leads to longer progression-free survival for epithelial ovarian carcinoma patients in the Rhone-Alpes region of France. Huguet M; Perrier L; Bally O; Benayoun D; De Saint Hilaire P; Beal Ardisson D; Morelle M; Havet N; Joutard X; Meeus P; Gabelle P; Provençal J; Chauleur C; Glehen O; Charreton A; Farsi F; Ray-Coquard I BMC Health Serv Res; 2018 Jan; 18(1):3. PubMed ID: 29301572 [TBL] [Abstract][Full Text] [Related]
68. High Expression of p21 as a Potential Therapeutic Target in Ovarian Clear-cell Carcinoma. Minagawa Y; Ishino K; Wada R; Kudo M; Naito Z; Takeshita T; Ohashi R Anticancer Res; 2020 Oct; 40(10):5631-5639. PubMed ID: 32988887 [TBL] [Abstract][Full Text] [Related]
69. Evaluation of CDK12 Protein Expression as a Potential Novel Biomarker for DNA Damage Response-Targeted Therapies in Breast Cancer. Naidoo K; Wai PT; Maguire SL; Daley F; Haider S; Kriplani D; Campbell J; Mirza H; Grigoriadis A; Tutt A; Moseley PM; Abdel-Fatah TMA; Chan SYT; Madhusudan S; Rhaka EA; Ellis IO; Lord CJ; Yuan Y; Green AR; Natrajan R Mol Cancer Ther; 2018 Jan; 17(1):306-315. PubMed ID: 29133620 [TBL] [Abstract][Full Text] [Related]
70. [Function of CDK12 in Tumor initiation and progression and its clinical consequences]. Vrábel D; Svoboda M; Navrátil J; Kohoutek J Klin Onkol; 2014; 27(5):340-6. PubMed ID: 25312711 [TBL] [Abstract][Full Text] [Related]
71. Discovery analysis of TCGA data reveals association between germline genotype and survival in ovarian cancer patients. Braun R; Finney R; Yan C; Chen QR; Hu Y; Edmonson M; Meerzaman D; Buetow K PLoS One; 2013; 8(3):e55037. PubMed ID: 23555554 [TBL] [Abstract][Full Text] [Related]
72. Dual Inhibition of CDK12/CDK13 Targets Both Tumor and Immune Cells in Ovarian Cancer. Cheng L; Zhou S; Zhou S; Shi K; Cheng Y; Cai MC; Ye K; Lin L; Zhang Z; Jia C; Xiang H; Zang J; Zhang M; Yin X; Li Y; Di W; Zhuang G; Tan L Cancer Res; 2022 Oct; 82(19):3588-3602. PubMed ID: 35857807 [TBL] [Abstract][Full Text] [Related]
74. Th e role of CDK12 in tumor bio logy. Dzimková M; Procházková J; Klát J; Kohoutek J Klin Onkol; 2020; 33(4):260-267. PubMed ID: 32894954 [TBL] [Abstract][Full Text] [Related]
75. RBM3-regulated genes promote DNA integrity and affect clinical outcome in epithelial ovarian cancer. Ehlén Å; Nodin B; Rexhepaj E; Brändstedt J; Uhlén M; Alvarado-Kristensson M; Pontén F; Brennan DJ; Jirström K Transl Oncol; 2011 Aug; 4(4):212-21. PubMed ID: 21804916 [TBL] [Abstract][Full Text] [Related]
76. Stable Chilà R; Chiappa M; Guffanti F; Panini N; Conconi D; Rinaldi A; Cascione L; Bertoni F; Fratelli M; Damia G Front Oncol; 2022; 12():903536. PubMed ID: 35912188 [TBL] [Abstract][Full Text] [Related]
77. Current progress and novel strategies that target CDK12 for drug discovery. Lei P; Zhang J; Liao P; Ren C; Wang J; Wang Y Eur J Med Chem; 2022 Oct; 240():114603. PubMed ID: 35868123 [TBL] [Abstract][Full Text] [Related]
78. Identification of polymorphisms in cancer patients that differentially affect survival with age. Doherty A; Kernogitski Y; Kulminski AM; Pedro de Magalhães J Aging (Albany NY); 2017 Oct; 9(10):2117-2136. PubMed ID: 29064820 [TBL] [Abstract][Full Text] [Related]
79. Predictive value of RAD51 on the survival and drug responsiveness of ovarian cancer. Feng Y; Wang D; Xiong L; Zhen G; Tan J Cancer Cell Int; 2021 May; 21(1):249. PubMed ID: 33952262 [TBL] [Abstract][Full Text] [Related]